-+ 0.00%
-+ 0.00%
-+ 0.00%

Drugs Made in America Acquisition II Receives $250,000 in Convertible Note Financing From Tal Alpha

PUBT·11/18/2026 16:09:46
Listen to the news
Drugs Made in America Acquisition II Receives $250,000 in Convertible Note Financing From Tal Alpha
  • Drugs Made in America Acquisition II received $250,000 from Tal Alpha Yezum Vekidum Asakim (2003) on November 6, 2026.
  • Total funding under the $1.4 million convertible notes financing reached $700,000, leaving $700,000 available.
  • Existing borrowings will become a single $700,000 convertible promissory note maturing June 30, 2027, extending prior notes’ December 2026 maturities.
  • Upon completion of a business combination, the investor may convert the note into combined-entity shares at a 35% discount to market price.
  • The investor’s funding commitment is not contingent on approval or closing of the proposed business combination with Alpha AI Biotech Group.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made in America Acquisition II Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-007137), on November 18, 2026, and is solely responsible for the information contained therein.